CARDIFF ONCOLOGY, INC. Proceeds from Insurance Settlement, Investing Activities
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Insurance Settlement, Investing Activities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromInsuranceSettlementInvestingActivities · last filed 2024-02-29
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for the quarter ending 2023-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for the quarter ending 2022-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for the quarter ending 2022-09-30 was $43.00K.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for the quarter ending 2021-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for fiscal 2022 was $114.00K.
- CARDIFF ONCOLOGY, INC. proceeds from insurance settlement, investing activities for fiscal 2021 was $0.00.
| Period end | Proceeds from Insurance Settlement, Investing Activities 3 month | Proceeds from Insurance Settlement, Investing Activities 6 month | Proceeds from Insurance Settlement, Investing Activities 9 month | Proceeds from Insurance Settlement, Investing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $43.00K derived: sum of 2 quarters · filed 2024-02-29 | $114.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $114.00K 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $71.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |